Almac Group, a contract development and manufacturing organization, has confirmed a EUR 16 million ($17.1 million) investment to expand its formulation and analytical development services to meet ongoing client demand at facilities in the Charnwood Campus in Loughborough, England.

The company successfully concluded negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, England, a science and technology and enterprise park. Specifically, Almac will occupy the formulation development and analytical testing facilities at the site, which will complement existing development andGMP services offered from its Craigavon Northern Ireland headquarters.

The Charnwood facilities were originally designed and built by a global pharmaceutical company as part of its in-house formulation development, clinical manufacturing, and analytical testing capabilities. Almac has now begun recommissioning of the facilities with operations focusing initially on expanding both non-potent and potent solid oral dose processing, creating approximately 180 new jobs in the next five years. With an initial investment into the Charnwood site of EUR 16 million ($17.1 million) in process and analytical technologies, an operational start date is targeted for the first quarter of 2017.

Source: Almac